In the past six years, the HARMONY Alliance has built a research infrastructure that facilitates state-of-the-art Big Data research projects in leukemia and other types of blood cancer. HARMONY invites hematologists to become involved and submit research proposals that utilize this infrastructure to improve the treatment of leukemia patients.
European LeukemiaNet (ELN ) is a highly valued Partner in the HARMONY Alliance. ELN is a publicly funded research network of excellence that aims to improve the treatment of leukemia through coordinated research efforts across Europe. The program will feature ELN recommendations for the treatment of AML, the paradigm shift in MPN, new developments in immunophenotyping, new approaches to treating R/R AML, and more. Download the detailed program of the symposium here >
HARMONY Partner Rüdiger Hehlmann, Professor of Medicine and founder/chair of ELN:
"HARMONY is focusing on a broad range of blood cancers, including acute and chronic leukemias, and ELN has has joined HARMONY from the start. By assembling anonymized data sets of thousands of patients into the unique HARMONY Big Data Platform, we can characterize the molecular landscape of these diseases, understand their pathophysiology, and identify novel drug targets. In addition, it will allow us to reliably predict disease course and drug response for subgroups of patients. HARMONY’s results should ultimately provide tools for healthcare professionals to rapidly select the most promising treatment for an individual patient with leukemia."
HARMONY & HARMONY PLUS session
HARMONY experts will present in session 3, which is scheduled at 18 April 2022 from 11:30-13:00. Find below an overview of our topics and speakers as well as the session program to download:
Big data to improve the care for leukemia patients
Learn more about our projects aiming to improve the treatment of ALL, AML, CLL, CML, MDS and MPN.
#bigdataforbloodcancer: Accelerating Better and Faster Treatment for Patients with Hematologic Malignancies.
The HARMONY Alliance (HARMONY and HARMONY PLUS) is a public-private European Network of Excellence for Big Data in Hematology. Our mission is to unlock and spread valuable knowledge on hematologic malignancies (blood cancers) among a large number of stakeholders, with the goal to harness and mine Big Data to speed up the development of improved treatments for patients and more effective treatment strategies. HARMONY is a partnership with more than 140 organizations such as hospitals, research institutes, patient organizations, pharmaceutical companies, regulatory agencies, IT companies, and medical network and associations such as ELN. Together, they have developed the HARMONY Big Data Platform and the HARMONY Datalake, which contains anonymized data records from tens of thousands of blood cancer patients. This unique research infrastructure, with advanced big data analytic and AI tools, is being used to accelerate the development of more effective treatments for patients with hematologic malignancies (blood cancers).
HARMONY has identified more than 156,000 patient datasets and has transferred more than 73,000 datasets into the HARMONY Big Data Platform. Careful procedures have been installed to ensure the anonymization and quality of the data. In addition, HARMONY data scientists have developed sophisticated methods for data harmonization and analysis. Dedicated Research Project teams are currently using the Big Data Platform to answer critical research questions that cannot be addressed with other methods.
Receive the latest news. Click here to subscribe!
HARMONY
Healthcare Alliance for Resourceful Medicine Offensive against Neoplasms in Hematology
HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).
HARMONY Coordination Office
Institute of Biomedical Research of
Salamanca (IBSAL)
Salamanca, Spain
HARMONY Communications
European Hematology Association (EHA)
The Hague, The Netherlands
Login
